In our study, we observed pronounced suppression of the PI3K/AKT and NF-κB signaling pathways as well as Bcl-xL, Bcl-2, and survivin by ursolic acid, which made it a promising candidate for potential treatment of oxaliplatin-resistant cancers. The gene discussed is BCL2L1; the disease is cancer.